$625 Million is the total value of Aisling Capital Management LP's 21 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ELEV | New | Elevation Oncology Inc. (ELEV) | $38,470,000 | – | 2,834,910 | +100.0% | 6.16% | – |
| GLUE | New | Monte Rosa Therapeutics Inc. (GLUE) | $33,422,000 | – | 1,472,331 | +100.0% | 5.35% | – |
| BMEA | New | Biomea Fusion Inc. (BMEA) | $12,469,000 | – | 798,757 | +100.0% | 2.00% | – |
| TALS | New | Talaris Therapeutics Inc. (TALS) | $10,032,000 | – | 682,923 | +100.0% | 1.61% | – |
| RPHM | New | Reneo Pharmaceuticals Inc. (RPHM) | $8,267,000 | – | 886,075 | +100.0% | 1.32% | – |
| VIRX | New | Viracta Therapeutics Inc. (VIRX) | $3,272,000 | – | 288,571 | +100.0% | 0.52% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-06
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Verona Pharma plc (VRNA) | 20 | Q3 2023 | 23.0% |
| AVROBIO, Inc. (AVRO) | 20 | Q3 2023 | 13.6% |
| Aclaris Theraputics Inc. (ACRS) | 20 | Q3 2023 | 6.6% |
| Aeglea Biotherapeutics Inc. (AGLE) | 19 | Q2 2023 | 7.5% |
| BridgeBio Pharma Inc. (BBIO) | 18 | Q3 2023 | 67.3% |
| Marker Therapeutics, Inc. (MRKR) | 18 | Q1 2023 | 11.7% |
| Atreca Inc. (BCEL) | 18 | Q3 2023 | 3.1% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 15 | Q3 2023 | 17.2% |
| Zosano Pharma Corporation (ZSAN) | 15 | Q2 2022 | 5.8% |
| ObsEva SA (OBSV) | 14 | Q1 2022 | 18.5% |
View Aisling Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-18 |
| 13F-HR | 2021-11-12 |
View Aisling Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.